Yoshito Komatsu

Hokkaido University Hospital

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (9)

Shunsuke Kondo

Tokyo Women's Medical University

Taroh Satoh

Osaka University Hospital

Tadamichi Denda

Kanagawa Cancer Center

Yasuyoshi Sato

University of Tokyo

Yosuke Togashi

Okayama University

Hiroshi Kawachi

Cancer Institute Hospital of Japanese Foundation for Cancer Research

Shogo Nomura

Project Lecturer

University of Tokyo

Satoshi Yuki

Hokkaido University Hospital

Hiromichi Ebi

Division Chief

Aichi Cancer Center

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yoshito Komatsu

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (9)

Shunsuke Kondo

Taroh Satoh

Tadamichi Denda

Yasuyoshi Sato

Yosuke Togashi

Hiroshi Kawachi

Shogo Nomura

Satoshi Yuki

Hiromichi Ebi

Make your next move.

Yoshito Komatsu

Research Interests

Explore related searches

Contact this professor

Articles (20)

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD)

Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment

Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial

Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors

Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer

Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B

A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

Correlation of <i>UGT1A1</i> Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

Collaborators (9)

Shunsuke Kondo

Taroh Satoh

Tadamichi Denda

Yasuyoshi Sato

Yosuke Togashi

Hiroshi Kawachi

Shogo Nomura

Satoshi Yuki

Hiromichi Ebi

Make your next move.